A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies

T. Hohdatsu, M. Nakamura, Y. Ishizuka, H. Yamada, and H. Koyama

Department of Veterinary Infectious Diseases, School of Veterinary Medicine and Animal Sciences, Kitasato University, Aomori-Ken, Japan

Accepted February 26, 1991

Summary. Enhancement of feline infectious peritonitis virus (FIPV) infection of feline macrophages was studied using monoclonal antibodies (MAbs) to the FIPV strain 79-1146. Adherent cells recovered from the feline lung and peritoneal cavity phagocytosed fixed red blood cells, and formed Fc-mediated rosettes. Enhancement of virus infection by MAb was investigated by inoculating alveolar macrophages with a mixtures of viral suspension and MAb, and examining the cells for intracellular viral antigen by the immunofluorescence assay and the amount of infectious virus in the supernatant fluid after incubation. The replication of FIPV in macrophages was enhanced by non-neutralizing MAbs recognizing peplomer protein (S) and transmembrane protein (M) of the virus. Even among the MAbs having the ability to neutralize FIPV strain 79-1146, some reversely enhanced virus infection when they were diluted. The enhancement was suppressed by pretreatment of the MAb with protein A. The enhancement was reduced by the use of F(ab')2 fragment of MAb. These results demonstrated antibody-dependent enhancement (ADE) of FIPV infection in macrophage. The replication of FIPV 79-1146 strain in macrophages from FIPV antibody-positive cats was more enhanced than in those from antibody-negative cats.

Introduction

Feline infectious peritonitis virus (FIPV), family Coronaviridae, genus Coronavirus, produces a chronic, progressive, immunologically-mediated disease in domestic and exotic cats. At the present time, no practical method of immunization has been reported. Cats immunized with virulence-attenuated live or inactivated FIPV are not protected against virulent FIPV challenge-exposure [15, 20]. Cats immunized with closely related coronaviruses, such as feline...
enteric coronavirus (FECV), canine coronavirus (CCV), and transmissible gastroenteritis virus (TGEV), are also sensitive to exposure to virulent FIPV [2, 16, 18, 22, 29]. Infection of FIPV and the onset of the disease are accelerated in cats with FIPV antibodies in comparison with those without FIPV antibody [17, 18, 27]. When cats passively immunized with FIPV antibodies were infected with virulent FIPV, severe symptoms were observed and some of them died soon after the infection [17, 27]. These phenomena are considered to have been caused by a mechanism similar to that of the dengue shock syndrome. Antibody-dependent enhancement (ADE) of viral infection, which occurs with sub-neutralizing antiviral antibodies and results from the formation of virus-antibody complexes, attachment of complexes to cell Fc receptors, and internalization by mononuclear phagocytes, has been demonstrated with some viral infections such as dengue virus infection [1, 4-6, 12–14, 25]. The feline macrophage is known to be one of the target cells for FIPV [7, 19, 28]. The in vitro growth of FIPV in feline macrophages has been reported by Stoddart and Scott [23, 24], but the details of ADE of FIPV infection are unknown. This paper describes in vitro ADE of FIPV infection in feline macrophages.

**Materials and methods**

**Virus**

The 79-1146 strain of FIPV was obtained from Dr. M.C. Horzinek of the State University Utrecht, the Netherlands, and the 79-1683 strain of FECV was obtained from Dr. A. J. McKeirnan of the Washington State University, Pullman. These strains were passaged 2 or 3 times in feline fetal cell cultures (fcwf-4), and stored at −80 °C until use.

**Monoclonal antibodies (MAbs)**

These were prepared by fusion of spleen cells from BALB/c mice immunized with the FIPV 79-1146 strain and mouse myeloma cells (P-3/x-63-Ag8-6, 5, 3). The MAbs used in the present study were F19-1, F18-2, and F30-1 recognizing protein M of the virus and F80-1, F25-1, 5-6-2, 6-4-2, and 7-4-1 recognizing protein S of the virus. Of these MAbs, 5-6-2, 6-4-2, and 7-4-1 have the ability to neutralize FIPV strain 79-1146, and recognize different epitopes of S protein of the virus. Other MAbs (F19-1, F18-2, F30-1, F80-1, and F25-1) have no neutralizing ability. These MAbs were characterized by the authors [8, 9]. The culture fluid of a hybridoma was used for the experiment.

**Collection of macrophages**

Macrophages were collected from coronavirus antibody-negative adult cats. Alveolar macrophages were obtained from alveolar washing with Hanks’s balanced salt solution (HBSS). The recovered cells were spun down, washed 3 times with HBSS and a 2 × 10⁶ cells/ml suspension was made in a growth medium (Eagle’s minimum essential medium containing 50% Leibovitz L-15 medium, 10% fetal calf serum, 100 units of penicillin per ml, and 100 µg of streptomycin per ml). The suspension was transferred in 1 ml volumes to each well of 24-well multiplates each of which contained a cover glass. The cells were incubated at 37 °C for 2 h, the supernatant fluid was removed, and the cell layers were washed with HBSS to remove non-adherent cells. After addition of growth medium the cells were
incubated at 37°C for 2 h, and washed with HBSS. The cells thus obtained were used as macrophages in the experiments.

Peritoneal macrophages were recovered from cats by lavaging the peritoneal cavity with HBSS 4 or 5 days after intraperitoneal administration of 100 ml/kg of liquid paraffin. The recovered cells were treated in the same manner as alveolar macrophages, and used for the experiments.

**Identification of macrophages**

Macrophages were identified on the basis of phagocytosis of fixed red blood cells and Fc-mediated rosetting. Phagocytosis was carried out by adding 0.5% sheep red blood cells (SRBC) fixed in 2.5% glutaraldehyde solution to cultured macrophages and incubating at 37°C for 2 h. After incubation, the cells were washed with phosphate buffered saline (PBS), fixed in methanol, and stained with 10% Giemsa solution. Fc-mediated rosetting was induced by adding SRBC coated with rabbit anti-SRBC antibodies to the cultured macrophages and incubating the mixture at 37°C for 1 h. After incubation, the specimens were gently washed with PBS, and observed under a microscope.

**Indirect fluorescent antibody assay (IFA)**

A mixture of MAbs that recognize peplomer protein (S), transmembrane protein (M) and nucleocapsid protein (N) of FIPV strain 79-1146 was used as the primary antibody. The MAbs were added to acetone-fixed cells and allowed to stand at 37°C for 30 min. After the specimens were washed with PBS three times, they were stained with rabbit antimouse-IgG, IgA and IgM serum conjugated with fluorescein isothiocyanate (Miles Laboratories, Naperville, U.S.A.). After left at 37°C for 30 min, they were washed with PBS, mounted in 50% glycerol buffer and observed under a fluorescence microscope.

**Plaque assay**

Confluent fcwf-4 cell monolayers in 60-mm plastic petri dishes were inoculated with virus dilution in 0.1 ml amounts. After virus adsorption at 37°C for 60 min, the inoculated cultures were covered with 5 ml of agar overlay medium which consisted of 1% Bacto agar in MEM. The cultures were incubated in a CO₂ incubator at 37°C for 2 days, and stained by incubating at 37°C for 6 h under a second overlay medium containing 0.01% neutral red. The infectious titer was expressed in plaque-forming units (PFU).

**ADE assay of viral infection**

Equal amounts of MAbs and viral suspension were allowed to react at 37°C for 1 h. The mixtures were inoculated in 0.1 ml volumes into wells of multiplate cultures of macrophages incubated for 3 days. After adsorption at 37°C for 1 h, 1 ml of growth medium was added, and incubated at 37°C for 36 h in a CO₂ incubator. The culture supernatant was determined for PFU, and the recovered cover slips were examined by IFA. The percentage of ADE was obtained by the following formula:

$$\text{percent of ADE} = \frac{A - B}{B} \times 100$$

where A is the rate of positivity of IFA or PFU in the presence of the antibodies and B is the rate of positivity of IFA or PFU in the absence of the antibodies.

**Pepsin digestion of MAb**

IgG was purified from mouse ascitic fluid by affinity chromatography using protein A sepharose 4B (Pharmacia, Sweden). The purified IgG was dialyzed against 0.2 M sodium
acetate buffer (pH 4.5), and 1 mg of pepsin per 100 mg of IgG was added to the specimen for digestion at 37 °C for 20 h. Subsequently, 1 N NaOH was added to adjust the pH to 8.0, and the reaction was terminated. The supernatant obtained after centrifugation at 2,000 x g for 30 min was loaded onto a protein A sepharose 4B column, and the flow-through fraction was used as the F (ab')\textsubscript{2} fragment. This fraction retained the IFA ability to detect FIPV antigen.

**Feline coronavirus antibody-positive cats**

Two feline coronavirus antibody-negative cats were orally inoculated with 10\textsuperscript{6} tissue culture infectious doses (TCID\textsubscript{50}) of the FECV strain 79-1683. After the antibodies to feline coronavirus were confirmed to be present by IFA technique and neutralization test 30 days after the inoculation, the cats were used to recover macrophages.

**Results**

Adherent cells recovered from the alveolus and peritoneal cavity of cats demonstrated the Fc-mediated rosetting and phagocytosis of fixed red cells (Fig. 1). Furthermore Giemsa staining showed more than 90% of the cells to have the morphology of macrophages.

Using MAbs recognizing protein M or S, ADE of feline macrophage infection with the FIPV 79-1146 strain was studied. Table 1 summarizes the results of MAbs without neutralizing ability. These MAbs were shown to enhance
Table 1. Antibody-dependent enhancement (ADE) by monoclonal antibody (MAb) without virus-neutralizing activity of feline macrophage infection with FIPV 79-1146 strain

| MAb no. | Indirect fluorescent assay | Plaque assay |
|---------|---------------------------|--------------|
|         | positive (%) | enhancement (%) | PFU/ml | enhancement (%) |
| F 19-1  | 3.8          | 171           | $7.9 \times 10^5$ | 229 |
| F 18-2  | 4.6          | 229           | $7.0 \times 10^5$ | 192 |
| F 30-1  | 3.3          | 136           | $9.0 \times 10^5$ | 275 |
| F 80-1  | 2.3          | 64            | $6.5 \times 10^5$ | 171 |
| F 25-1  | 3.8          | 171           | $5.4 \times 10^5$ | 125 |
| Without MAb | 1.4       | —             | $2.4 \times 10^5$ | —  |

infection by both the indirect fluorescence assay (IFA) and the plaque assay. The enhancement demonstrated by IFA decreased with the antibody dilution (Fig. 2). Figure 3 shows the results of enhancement detected by IFA for neutralizing MAbs 5-6-2 [neutralization (NT) titer; 1:128], 6-4-2 (NT titer; 1:256) and 7-4-1 (NT titer; 1:64). Virus infection was completely inhibited by MAb 5-6-2 at a dilution of 1:100 or less. At a dilution of more than 1:100, no enhancement was observed. Undiluted MAb 6-4-2 and 7-4-1 inhibited virus infection, but at a dilution of 1:10 infection was reversely enhanced. MAb 6-4-2 induced a particularly strong enhancement.

Effects of blockade of the Fc region of MAb on ADE of viral infection were studied. Protein A (Pharmacia, Sweden) was diluted to 0.05–500 µg/ml, and added to F18-2 MAb. The mixture was allowed to stand at 4°C for 1 h. Viral suspension was added to the mixture, incubated at 37°C for 1 h, and

![Graph](image-url)

**Fig. 2.** Relationship between the dilution of antibody and the enhancement of IFA.
Fig. 3. Antibody-dependent enhancement (ADE) by monoclonal antibody (MAb) with virus-neutralizing activity of feline macrophage infection with FIPV 79-1146 strain. MAbs: a 5-6-2, b 6-4-2, c 7-4-1

inoculated onto alveolar macrophages. ADE was suppressed with increasing concentration of protein A (Fig. 4). Effects on ADE of IgG purified from mouse ascitic fluid and F(ab')2 fragment in which the Fc fragment was removed from IgG by digestion with pepsin were studied in alveolar macrophages. The percent enhancement was determined by IFA. Regardless of the concentration of antibody, ADE was more suppressed by F(ab')2 fragment than by IgG (Fig. 5).

Macrophages were recovered from the alveolus and peritoneal cavity of 2 cats experimentally infected with the FECV 79-1683 strain and of 2 coronavirus antibody negative cats. Alveolar and peritoneal macrophages, incubated for 3 days, were inoculated with the FIPV 79-1146 strain. Thirty-six hours later the virus replication in these cells was compared. Table 2 shows the results. Virus replication was distinctly better in the peritoneal and alveolar macrophages recovered from the antibody-positive cats than those from the antibody-negative cats. When no virus was inoculated onto the macrophages recovered from the antibody-positive cats, of course no viral antigen was detected by IFA, and no infectious virus was found even in the culture supernatant. When the peritoneal and alveolar macrophages were compared, viral replication tended to be better
Antibody-dependent enhancement of FIPV infection

Fig. 4. Effect of protein A on antibody-dependent enhancement of FIPV strain 79-1146 infection in feline alveolar macrophages

Fig. 5. Effect of pepsin-digested IgG on antibody-dependent enhancement of FIPV strain 79-1146 infection in feline alveolar macrophages

in the peritoneal macrophages from both the antibody-negative and -positive cats.

Discussion

The in vitro growth of FIPV was first demonstrated in cultures of cells from the peritoneal exudate of an experimentally infected kitten in 1976 [19]. Macrophages in inflammatory lesions of the infected cat were shown to contain virus by the electron microscopic observation, suggesting the macrophage to
Table 2. Replication of FIPV strain 79-1146 in macrophages from feline coronavirus antibody-negative and -positive cats

| Cell                        | Assay | Antibody-negative cats (mean) | Antibody-positive cats (mean) |
|-----------------------------|-------|-------------------------------|-------------------------------|
| Peritoneal macrophages      | IFA<sup>a</sup> | 3.83%                         | 15.94%                        |
|                             | Plaque<sup>b</sup> | $2.3 \times 10^5$             | $34.5 \times 10^5$           |
| Alveolar macrophages        | IFA   | 2.11%                         | 10.14%                        |
|                             | Plaque | $1.9 \times 10^5$             | $20.5 \times 10^5$           |

<sup>a</sup> Percentage of IFA positive cells  
<sup>b</sup> PFU/ml

be one of the target cells for FIPV [19]. Stoddart and Scott have recently reported the growth of FIPV in macrophages recovered from the peritoneal cavity [23, 24]. In the present study adherent cells recovered from the alveolus and peritoneal cavity phagocytosed fixed red blood cells and were able to form Fc-mediated rosettes. These phenomena indicate the adherent cells to have properties of macrophages. When the adherent cells were inoculated with the FIPV 79-1146 strain, about 1–2% of the cells were revealed to be virus antigen-positive by the indirect fluorescence assay, and the supernatant fluid contained $2 \times 10^5$ PFU/ml of virus. However, no cytopathic effect was observed, suggesting the infection to be persistent and lead to a virus-carrier state.

Antibody-bound virus invades cells via Fc receptors and infection is enhanced. This phenomenon has been observed in macrophages and macrophage-like cell lines with various viruses [1, 4–6, 12–14, 25]. The present study disclosed that viral infection of alveolar macrophages is enhanced by intervention with MAbs without virus neutralizing activity (Table 1). The enhancement was suppressed by blockade of the Fc region of antibody (Figs. 4 and 5). Even of the MAbs having the ability to neutralize FIPV strain 79-1146, some reversely enhanced the infection after they were diluted (Fig. 3b and c). Each of the neutralizing MAbs used in this study recognizes the different epitopes of protein S of the virus. MAb 5-6-2 showed no enhancement of infection regardless of dilution (Fig. 3a). The inhibition of virus proliferation by the MAb may be exerted after adsorption of viruses to cells. Detailed mechanisms of neutralization and enhancement of FIPV infection by these neutralizing MAbs should be further studied. A difference in viral type is considered to be closely related to the ADE of infection and to cause dengue shock syndrome in dengue virus infection [6, 14]. We discovered the existence of at least 2 sero types of FIPV by using MAbs with ability to neutralize FIPV strain 79-1146 [8]. Effects of this type difference on ADE of FIPV infection should be studied in future.

Vennema et al. combined protein S gene of FIPV with vaccinia virus [26]. Cats immunized with the recombinant virus demonstrated no protection against
Antibody-dependent enhancement of FIPV infection

The onset of disease was accelerated by the immunization. This observation is further supported by our results indicating the MAb to protein S to show ADE. Furthermore, the present study showed that the MAb to protein M also has the enhancing activity.

FECV is known to be antigenically cross-reactive with FIPV. Cats previously inoculated with FECV showed an accelerated onset of the disease upon infection with virulent FIPV [16–18]. The replication of FIPV was distinctly better in macrophages recovered from FECV antibody-positive cats than in those from antibody-negative cats. It also remains unsolved whether this interesting phenomenon is due to ADE by cytophilic antibody [21] or not. Some studies have shown that viral growth is better in activated macrophages [3, 10]. We also obtained better replication of FIPV in peritoneal macrophages induced by stimulation with liquid paraffin than in alveolar macrophages (Table 2). ADE of FIPV infection should also be studied by taking into consideration a difference in the activation of macrophages. The possibility of using fcwf-4 cells, which are believed to have macrophage properties [11], for the determination of ADE of FIPV infection is under investigation, taking cell homogeneity into consideration.

Acknowledgements

This work was supported in part by grants from the Ministry of Education, Science and Culture, Japan.

References

1. Brandt WE, McCown JM, Gentry MK, Russell PK (1982) U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect Immun 36: 1036–1041
2. Barlough JE, Stoddart CA, Sorresso GP, Jacobson RH, Scott FW (1984) Experimental inoculation of cats with canine coronavirus and subsequent challenge with feline infectious peritonitis virus. Lab Anim Sci 34: 592–597
3. Cardosa M J, Gordon S, Hirsch S, Springer TA, Porterfield JS (1986) Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. J Virol 57: 952–959
4. Halstead SB, O'Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265: 739–741
5. Halstead SB, O'Rourke EJ (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by nonneutralizing antibody. J Exp Med 146: 201–217
6. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK (1984) Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 132: 1529–1532
7. Hayashi T, Goto N, Takahashi R, Fujiiwa K (1978) Detection of coronavirus-like particles in a spontaneous case of feline infectious peritonitis. Jpn J Vet Sci 40: 207–212
8. Hohdatsu T, Okada S, Koyama H (1991) Characterization of monoclonal antibodies against feline infectious peritonitis virus type II and antigenic relationship between feline, porcine, and canine coronaviruses. Arch Virol 117: 83–95
9. Hohdatsu T, Sasamoto T, Okada S, Koyama H (1991) Antigenic analysis of feline coronaviruses with monoclonal antibodies (MAbs): preparation of MAbs which discriminate between FIPV strain 79-1146 and FECV strain 79-1683. Vet Microbiol (in press)

10. Hotta H, Hotta S, Takada H, Kotani S, Tanaka S, Ohki M (1983) Enhancement of dengue virus type 2 replication in mouse macrophage cultures by bacterial cell walls, peptidoglycans, and a polymer of peptidoglycan subunits. Infect Immun 41: 462–469

11. Jacobse-Geels HEL, Horzinek MC (1983) Expression of feline infectious peritonitis coronavirus antigens on the surface of feline macrophage-like cells. J Gen Virol 64: 1859–1866

12. Kimura T, Ueba N, Minekawa Y (1981) Studies on the mechanism of antibody-mediated enhancement of Getah virus infectivity. Biken J 24: 39–45

13. Klits SC, Halstead SB (1980) An explanation for enhanced virus plaque formation in chick embryo cells. Nature 285: 504–505

14. Morens DM, Venkateshan CN, Halstead SB (1987) Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J Gen Virol 68: 91–98

15. Pedersen NC, Black WB (1983) Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 44: 229–234

16. Pedersen NC, Boyle JF, Flood K, Fudge A, Barker J (1981) An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res 42: 368–377

17. Pedersen NC, Boyle JF (1980) Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 41: 868–876

18. Pedersen NC, Evermann JF, McKeirnan AJ, Ott RL (1984) Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683. Am J Vet Res 45: 2580–2585

19. Pedersen NC (1976) Morphologic and physical characteristics of feline infectious peritonitis virus and its growth in autochthonous peritoneal cell cultures. Am J Vet Res 37: 567–572

20. Pedersen NC (1987) Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 218: 529–550

21. Schultz RM, Woon MC, Tompkins AF (1974) Macrophage immunity to vaccinia virus: factors affecting macrophage immunity in vitro. J Reticuloendothel Soc 16: 37–47

22. Stoddart CA, Barlough JE, Baldwin CA, Scott FW (1988) Attempted immunisation of cats against feline infectious peritonitis using canine coronavirus. Res Vet Sci 45: 383–388

23. Stoddart CA, Scott FW (1989) Intrinsic resistance of feline peritoneal macrophages to coronavirus infection correlates with in vivo virulence. J Virol 63: 436–440

24. Stoddart CA, Scott FW (1988) Isolation and identification of feline peritoneal macrophages for in vitro studies of coronavirus-macrophage interactions. J Leuko Biol 44: 319–328

25. Takeda A, Tuazon CU, Ennis FA (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242: 580–583

26. Vennema H, Groot RJ, Harbour DA, Daldorup M, Gruffydd-Jones T, Horzinek MC, Spaan WJM (1990) Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64: 1407–1409

27. Weiss RC, Scott FW (1981) Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 4: 175–189

28. Weiss RC, Scott FW (1981) Pathogenesis of feline infectious peritonitis: nature and development of viremia. Am J Vet Res 42: 382–390
29. Woods RD, Pedersen NC (1979) Cross-protection studies between feline infectious peritonitis and porcine transmissible gastroenteritis viruses. Vet Microbiol 4: 11–16

Authors' address: T. Hohdatsu, Department of Veterinary Infectious Diseases, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, 034, Japan

Received February 25, 1991